07:00 , Jun 3, 2013 |  BioCentury  |  Finance

Seeds to trees

Flush with cash from its existing holdings and not seeing enough worthwhile venture deals to spend it on, Novo A/S has decided to expand its growth equity investments in mature companies. After a proof-of-principle deal...
08:00 , Dec 22, 2003 |  BC Week In Review  |  Company News

Schering-Plough, Chr. Hansen Holding A/S deal

SGP said it will not take an option to license Prograss, an oral tablet to treat grass pollen allergy from CHRH's ALK-Abello subsidiary. Under a 2002 deal, the companies partnered for Phase IIb/III development of...
08:00 , Oct 28, 2002 |  BC Week In Review  |  Company News

Schering-Plough, Chr. Hansen Holding A/S deal

SGP and CHRH's Alk-Abello subsidiary partnered to run a Phase IIb/III Prograss trial of Alk-Abello's oral tablet to treat grass pollen allergy. The double-blind, placebo-controlled trial is expected to start in the first quarter of...
08:00 , Feb 12, 2001 |  BC Week In Review  |  Company News

Maxygen, Chr. Hansen Holding A/S deal

MAXY and CHRH's ALK-Abello A/S subsidiary will develop recombinant allergy therapeutics. The three-year deal will combine MAXY's MolecularBreeding directed evolution technology with ALK-Abello's allergen pipeline. ALK-Abello will have exclusive worldwide commercialization rights to resulting compounds....